Transaction · 0001193125-26-377207

Banerjee Subhashis

Banerjee Subhashis, CMO, reported a transaction classified as exercise at Artiva Biotherapeutics, Inc. involving 5306.000000 shares for an estimated $0.00. Reported holdings after the transaction were 74265.000000 shares. The stored filing text includes a detected 10b5-1 reference.

exerciseSEC transaction code MCMO
ARTVArtiva Biotherapeutics, Inc.
Trade date
Aug 27, 2026
Filing date
Aug 31, 2026
View on SEC Insider profile
Estimated value$0Shares × reported price
Shares traded5.30k$0.00 per share
Holdings after74.2kDirect
% of reported position tradedUnavailableThis security and ownership context
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

ARTV price since this filing

Daily closing prices, with the filing date and available return windows
ARTV · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago -6.8%1w ago -1.4%1d ago +4.2%
Returns since7d -1.0%30d -37.0%90d180d1y

Transaction facts

Stored Form 4 columns with their raw values

Derivative
Type
exercise
Code M
Identifier
0001193125-26-377207
Employee Stock Option (Right to Buy)
Transaction date
Aug 27, 2026
Filed Aug 31, 2026, 11:06 PM · 4d delay
Shares
5,306 sh
$0.00 per share
Estimated value
$0
Computed from shares × price
Holdings after
74,265 sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Derivative Transaction Direct Ownership 10b5-1 Detected
Filing-only score

-20 points

Compact filing score computed from stored Form 4 facts. Version v1.

Low filing signal

This filing has a meaningfully negative filing-only score. It is likely less useful as a positive insider-activity signal.

How this score is calculated
  • direct_ownership+6 points

    direct_or_indirect_ownership = D

    Direct ownership reports the insider's personal stake.
  • derivative_transaction-16 points

    is_derivative = true

    Derivative exercise rows are less discretionary than open-market purchases.
  • tenb5_1_detected-10 points

    is_10b5_1 = true

    Stored filing content includes detected 10b5-1 language.
Read the scoring methodology

Signed filing-only points, not a probability or expected return. Version v1.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

Chief Medical Officer

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    The reported transactions occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 14, 2026.

  2. F2

    The weighted average sale price for the transaction reported was $12.0087, and the range of prices were between $12.00 and $12.05, inclusive. Upon request by the SEC staff, the Issuer, or any security…

  3. F3

    25% of the shares initially subject to the option vested and became exercisable on April 8, 2026, and the balance of the shares subject to the option are vesting and becoming exercisable at a rate of…

Original filing · 0001193125-26-377207
Related transactions

0 other transactions

Same SEC filing
Recent company activity

0 recent txs

ARTV